Circulating tumor DNA in breast cancer in 2027: advancing liquid biopsy and molecular monitoring.
PURPOSE OF REVIEW Circulating tumor DNA (ctDNA) is increasingly used for molecular profiling in breast cancer, and its role as a longitudinal biomarker is expanding. This review examines recent evidence on serial ctDNA assessment, focusing on minimal residual disease (MRD) and molecular relapse in early breast cancer (...